Loxo, the AI recruiting platform purpose-built for direct hire and executive search firms, announced today a renewed ...

Bayer will pay $400 million -- and up to $1.15 million more in milestones tied to regulatory approvals and sales -- for partial commercial rights to two rare cancer drugs being developed by Loxo ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

We have previously highlighted Loxo Oncology (Nasdaq: LOXO) in this space regarding its partnership with Illumina on next generation cancer diagnostics. One of the collaborative efforts involves a ...

Months after the Food and Drug Administration approved one of the first drugs to win a tissue-agnostic, biomarker-driven label, another company hopes to become the second to receive an approval for a ...

A drug for patients who have become resistant to marketed members of a class of therapies commonly used to treat certain blood cancers has shown broad activity in patients, regardless of whether they ...

Filming nude scenes helped Sarah Shahi embrace her body. Playing an unhappy wife made her realize she should get a divorce. Think Myles Garrett broke the single-season sack record? 1 NFL Hall of Famer ...

Every time Lydia Ramsey Pflanzer publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive ...

In some ways, this is the most exciting FDA approval of the year, but don't look for blockbuster sales. Unfortunately for Loxo, earning an approval for Vitrakvi could be easier than marketing it. Here ...

Shares of Loxo Onocology Inc. were indicated up about 33% in premarket trade Monday, after the biopharmaceutical company agreed to be acquired by Eli Lilly & Co. in a deal valued at $8.0 billion.

"We look to generate crazy over-the-top exciting data that is great for patients,” Loxo CEO Josh Bilenker, pictured alongside chief business officer Jacob Van Naarden (left), told Forbes last year. A ...